Factor Xa Inhibitors in Coronary Artery Disease

Slides:

Advertisements

Similar presentations

Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.

Advertisements

¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

The Anglo Scandinavian Cardiac Outcomes Trial

First time a CETP inhibitor shows reduction of serious CV events

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Oral Anticoagulation and Preventing Stent Thrombosis

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Bleeding and cancer risk in patients with vascular disease COMPASS Steering Committee and Investigators.

Atrial Fibrillation and PCI

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

When Is Adding Aspirin to NOACs Worth the Risk?

NOACs in Clinical Practice: Are They All the Same?

New Strategies to Prevent CV Events After Hospital Discharge

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Unmet Needs in the Secondary Prevention in ACS

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Select Topics in Cardiovascular Medicine

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Recurrent Angina: New Tools for an Old Problem

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Treatment Options to Consider

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

NOACS: Emerging data in ACS/IHD

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

Understanding PAD.

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Risk Stratification in CAD and PAD

CV Risk Doesn't End in the Cath Lab

Identifying High-Risk AF Patients

Factor Xa Inhibitors in PAD

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

CAD/PAD in Primary Care

CAD and HF Often Coexist

Antithrombotic Therapy in PAD

Antithrombotic Therapy in Vascular Protection: From CAD to HF

LDL Cholesterol.

Antithrombotics in Arterial Disease: Focus on Coronary Disease

How to Optimize Cholesterol Management in High-Risk CV Patients

Program Goals Background: Anticoagulation in Patients With VTE.

Elevated Admission Plasma Glucose Following ACS

Reducing Risk for CV Outcomes

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Reassessing Risk Stratification in CAD/PAD

Section C: Clinical trial update: Oral antiplatelet therapy

Presentation transcript:

Factor Xa Inhibitors in Coronary Artery Disease

Targets of Antithrombotic Agents

EUCLID Ticagrelor vs Clopidogrel for PAD

COMPASS Selected Exclusion Criteria

COMPASS Inclusion Criteria

COMPASS Efficacy Outcomes

ATLAS ACS 2 -- TIMI 51 Rivaroxaban vs Placebo After ACS

ATLAS ACS-TIMI 46 Dose-Escalation Study in Patients After ACS

ATLAS ACS 2 -- TIMI 51 Bleeding Outcomes

COMPASS CAD and PAD Cohorts

COMPASS Background Therapy

COMPASS Patients with CAD and PAD

COMPASS Stroke Outcomes

REACH Registry CV Event Rates in Stable Outpatients at Risk of or With Atherothrombosis

COMPASS PAD Cohort Peripheral Limb Outcomes

Clinical Applicability of COMPASS

Current and Future Antithrombotic Regimens

Clinical Applicability of COMPASS

Efficacy of Antithrombotic Secondary Prevention in Stable Vascular Disease

Comparison of Guideline-Indicated Secondary Prevention Therapies and CV Risk Reduction

COMPASS Bleeding Outcomes

COMPASS CAD Cohort Analysis of Major Bleeding

External Applicability of the COMPASS Trial REACH Registry

Potential Candidates for Rivaroxaban Therapy

COMPASS PAD Cohort Patients Who Benefited From Therapy

Correct Dose of Rivaroxaban

Summary

Abbreviations

Abbreviations (cont)